Connect with us

BUSINESS

GT Biopharma Inc (OTCMKTS:GTBP) Achieves Success in Treating Solid Tumors Using Trispecific Killer Engagers

Published

on

GT Biopharma Inc (OTCMKTS:GTBP) has announced the success of its next generation TriKEs (Trispecific Killer Engagers) for the treatment of solid tumors. The team consisting of Dr. Martin Felices, Co-Director (Translational Therapy Laboratory) at University of Minnesota, and Dr. Daniel Vallera, Director (Section of Molecular Cancer Therapeutics) have headed the development efforts of these next generation treatments.

They have conducted the trial on two animal models. In one case, they have carried out the trial to treat neck and head cancers and in another tried to cure ovarian cancer. The animal with ovarian cancer, which is treated using CD16-IL15-B7H3 TriKE, has exhibited considerable improvement in the treatment of a tumor.

Also, the animal model with neck and head cancer has shown a considerable reduction in tumor when treated with CD16-IL15-EpCAM TriKE. The new developments are expected to satisfy the unmet needs of patients suffering from the solid tumor that accounts for 80% of the cancer cases. There is a great need for the treatment of patients suffering from neck and head and ovarian cancers.

According to Dr. Martin Felices, further investigation is necessary to ascertain the effectiveness of the new formulations in curing the head and neck and ovarian cancers in humans. Commenting on the development and the trial results of TriKEs, Dr. Daniel Vallera said the new formulation is highly effective to treat hard to cure cancers.

Dr. Raymond Urbanski, Chief Executive Officer and Chairman of GT Biopharma Inc, said the trial results of TetraKE and TriKE platforms are encouraging to cure solid and liquid tumors.

GT Biopharma Inc Collaborates with Roche/Genentech and Affimed to validate NK cell hypothesis

GT Biopharma collaboration with Roche/Genentech and Affimed involves royalty and milestone payments of $5 billion and upfront payments of $96 million. The collaboration allows the company to validate the effectiveness of the natural killer cell hypothesis. The company has been putting considerable efforts to bring the TetraKE and TriKE engager platforms into the clinical development complying with regulatory requirements.

Though GT Biopharma and Affimed are similar, they differ in the construction of proteins and addressing NK cell activation. The collaboration of both the firms will help to deliver promised NK cell-engager therapies.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BUSINESS

Fiore Cannabis Ltd (OTCMKTS: FIORF) Moving Forward With Expansion Of Apex Cultivation Facility

Published

on

Fiore Cannabis Ltd (OTCMKTS:FIORF) has signed a Letter of Intent to sell a surplus cultivation license for its Apex cannabis cultivation and production facility in Las Vegas to Allied Corp. The non-binding agreement was signed on February 15, 2021. Fiore Cannabis will seal the deal through a wholly-owned subsidiary.

The deal, which is valued at $1.5 million, will be completed after a definitive agreement, which is expected to be completed 30 days after the Letter of Intent. Fiore Cannabis Ltd has licenses for cannabis cultivation, production, and sale in various states. On the other hand, Allied is working on increasing its footprints in the international medical and specialty cannabis space.

In a statement, Fiore Cannabis President and CEO Erik Anderson said the deal will help the company further strengthen its strategic plans. Money from the sale will be used to speed up Fiore’s expansion plans for its Apex facility. The company is expanding its plant to boost production capacity and meet growing demand in the Nevada market.

The two companies have developed working guidelines that will guide their operations and interaction as Allied constructs a facility that Fiore will operate through a pre-negotiated partnership. The companies will also negotiate a revenue-sharing agreement for incremental sales from the facility.

Fiore will leverage its expertise to assist with genetic sorting and selection of high-yield cannabis strains for Allied. In addition, Fiore will offer consultancy services to guild sales and marketing of the final cannabis products. The company enjoys a wide network of established retail stores and medical dispensaries.

Funds raised from this deal will be used to expand Apex’s facility. Currently, the two companies are exploring ways to increase cultivation space to boost production quantities.

Fiore recently announced that it is actively pursuing its plan to refocus its assets in California and Nevada’s key markets. The company says these operations helped improve its Adjusted EBITDA for January.

According to Erik, the new plan will enable them focus their effort and resources on high-yielding activities and produce high-quality cannabis products as it seeks to establish strong footprints in growing markets.

Continue Reading

BUSINESS

Ayr Wellness Inc (OTCMKTS: AYRWF) Finalizing merger agreement with Blue Camo, LLC (Arizona)

Published

on

Ayr Wellness Inc (OTCMKTS:AYRWF) is in the final stages of acquiring 100% interest in Blue Camo, LLC. The deal comes after a previously signed Letter of Intent. Ayr Strategies is a specialist in medical cannabis with operations in several states across the US.

In an announcement late last year, Ayr laid out plans to acquire 100% interest in Blue Camo, LLC, which has its operations in Arizona. Ayr will also acquire all Blue Camo’s assets, including a cultivation facility under construction in Phoenix measuring 80,000 ft2, a 10,000 ft2 triple-stacked cultivation and processing facility in Chandler, and three Oasis-branded dispensaries in the greater Phoenix area.

In a statement, Ayr Strategies said Arizona has been on the list of attractive markets for cannabis for a long time, ranking third in the US in terms of patient penetration. The company noted that the medical cannabis market in Arizona is worth $1 billion. This figure is expected to go up following a decision by the Arizona Department of Public Health to approve the recreational use of cannabis.

The department has already approved around 90 locations, including three that Ayr Strategies are acquiring. The three Oasis-branded dispensaries have been approved for adult-use sales and started operations at the start of this year.

Under the agreement, Ayr Strategies will pay a down payment of $75.4 million, split between $9.5 million in cash and $37.4 million in stock. Ayr Strategies will also deposit 2 million shares in escrow to be released after attaining the new facility’s required production targets.

Ayr Strategies announces change of corporate name

Ayr Strategies Inc has changed its corporate name to Ayr Wellness Inc. The change took effect on February 12.

In a statement, Ayr Wellness Chairman and Chief Executive Officer Jonathan Sandelman said the change was motivated by the desire to better reflect the company’s mission of offering premium quality cannabis. Also, he said they are working at improving customer experience, and establishing the company as a voice of authority in the industry.

Sandelman also said Ayr Wellness will work towards enriching their customers’ lives. This, he said, will be achieved through the cultivation of high-quality plants and processing high-quality cannabis.

Continue Reading

BUSINESS

Axim Biotechnologies Inc (OTCMKTS:AXIM) Files Amended EUA for Portable 1 Rapid Diagnostic Test for Neutralizing Antibodies

Published

on

AXIM® Biotechnologies, Inc has submitted its amended Emergency Use Authorization (EUA) application with the US Food and Drug Administration (FDA). The application was first filed in September last year to secure authorization to use rapid kits in measuring COVID-19 neutralizing antibodies in serum and plasma. AXIM offers healthcare solutions targeting oncological and COVID-19 research.

The latest application includes an amended EUA that has positive outcomes from a Biosafety Level 3 (BSL-3). In the latest study, researchers managed to positively correlate the rapid 10-minute lateral flow assay test to measure the level of COVID-19 neutralizing antibodies in plasma.

When used to detect neutralizing antibodies, AXIM’s ImmunoPass was found to have 97.8% accuracy. This is compared to 85.8% accuracy reported by VITROS® Total an IgG COVID-19 Antibody Test produced by Ortho Clinical Diagnostics.

In a statement, John W. Huemoeller II, the CEO of AXIM® Biotech, said, With this amended EUA, we are one step closer to our goal of providing an ‘Immunity Passport’ through our accurate, fast and relatively inexpensive COVID-19 neutralizing antibody test. Our assay is the only functional test that measures levels of neutralizing antibodies in serum, plasma or whole blood.”

Around the world, countries are in a rush to ship and administer COVID-19 vaccines. AXIM’s rapid will be vital in conducting tests to determine if the vaccines produced the desired response. In particular, rapid diagnostic tests will be used to determine whether the vaccines produce high levels of neutralizing antibodies.

With time, the test will be used to monitor the impact of the vaccines to determine if a booster is needed in the future. Another test is needed to determine the level of neutralizing antibodies in convalescent plasma.

The company’s product in the second application will measure the rate of neutralizing antibodies in convalescent plasma to identify plasma with the highest levels of neutralizing antibodies. Plasma with high levels of neutralizing antibodies will then be used to fight COVID-19.

In 2020, the company entered into an exclusive limited licensing, manufacturing, and distribution agreement with Empowered Diagnostics LLC that gave the later rights for large-scale production of the rapid diagnostic tests.

Continue Reading

Trending Stories